Gan & Lee Pharmaceuticals Co., Ltd. (SHSE: 603087) has announced that its wholly-owned European subsidiary, Gan & Lee Pharmaceuticals Europe GmbH, has recently received a drug registration approval from the United Arab Emirates' Ministry of Health and Prevention (MOHAP) for its Insulin Glargine Injection (pre-filled pen).
Insulin Glargine is a long-acting basal insulin administered via a single daily subcutaneous injection, providing blood glucose-lowering effects that last for 24 hours. It is characterized by its prolonged duration of action, stable and peak-free blood concentration profile, and consistent glycemic control.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments